Oseltamivir phosphate, known commercially as Tamiflu, is an antiviral medication used to treat and prevent influenza A and B. The original patent for oseltamivir was filed by Gilead Sciences and later licensed to Roche.
When do oseltamivir patents expire?
The primary patents covering oseltamivir have largely expired in major markets. For instance, key patents in the United States expired around 2016, and similar expirations occurred in Europe around the same period [1]. These expirations have opened the door for generic versions of the drug to enter the market.
Can generic oseltamivir be produced now?
With the expiry of the main patents, generic manufacturers are able to produce and market oseltamivir. The availability of generic oseltamivir can lead to lower prices for the medication.
What is the mechanism of action for oseltamivir?
Oseltamivir is a prodrug that is hydrolyzed in the liver to its active form, oseltamivir carboxylate. Oseltamivir carboxylate is a selective inhibitor of the influenza virus neuraminidase enzyme [2]. Neuraminidase is crucial for the release of newly formed virions from infected host cells and for their subsequent spread. By inhibiting this enzyme, oseltamivir prevents the replication and spread of the influenza virus in the body.
What are the potential risks or side effects of oseltamivir?
Common side effects associated with oseltamivir include nausea and vomiting. Less common but more serious side effects can include neuropsychiatric events, such as delirium and hallucinations, particularly in children and adolescents [3]. Patients with severe kidney disease may require dose adjustments.
How does oseltamivir compare to other influenza treatments?
Oseltamivir is one of several antiviral medications available for influenza. Other neuraminidase inhibitors include zanamivir (Relenza) and peramivir (Rapivab). Baloxavir marboxil (Xofluza) is a different class of antiviral that inhibits the cap-dependent endonuclease of the influenza virus polymerase complex. The choice of treatment often depends on factors such as the specific influenza strain, patient characteristics, and potential for drug resistance.
Who are the main manufacturers of oseltamivir?
Roche is the originator and primary manufacturer of the branded oseltamivir, Tamiflu. Following patent expirations, numerous generic pharmaceutical companies have entered the market, producing their own versions of oseltamivir.
Where can I find more information on drug patents like oseltamivir?
Information on drug patents, including their expiry dates and status, can be found on specialized resources like DrugPatentWatch.com [1].
What is the clinical efficacy of oseltamivir?
Clinical trials have demonstrated that oseltamivir can reduce the duration of influenza symptoms by approximately one to two days and decrease the risk of influenza-related complications, such as pneumonia and hospitalization, when administered early in the course of illness [2]. Its effectiveness is greatest when started within 48 hours of symptom onset.
What is the regulatory status of oseltamivir?
Oseltamivir is approved by regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment and prevention of seasonal and pandemic influenza.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146667/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349797/